<code id='64DD904210'></code><style id='64DD904210'></style>
    • <acronym id='64DD904210'></acronym>
      <center id='64DD904210'><center id='64DD904210'><tfoot id='64DD904210'></tfoot></center><abbr id='64DD904210'><dir id='64DD904210'><tfoot id='64DD904210'></tfoot><noframes id='64DD904210'>

    • <optgroup id='64DD904210'><strike id='64DD904210'><sup id='64DD904210'></sup></strike><code id='64DD904210'></code></optgroup>
        1. <b id='64DD904210'><label id='64DD904210'><select id='64DD904210'><dt id='64DD904210'><span id='64DD904210'></span></dt></select></label></b><u id='64DD904210'></u>
          <i id='64DD904210'><strike id='64DD904210'><tt id='64DD904210'><pre id='64DD904210'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:focus    - browse:3
          Micrograph of ulcerative colitis -- biotech coverage from STAT
          Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

          Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

          The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

          advertisement

          It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment